Literature DB >> 26676684

Possible pharmacotherapy for nifedipine-induced gingival overgrowth: 18α-glycyrrhetinic acid inhibits human gingival fibroblast growth.

R Takeuchi1, K Hiratsuka1, K Arikawa2, M Ono3, M Komiya3, Y Akimoto3, A Fujii4, H Matsumoto5.   

Abstract

BACKGROUND AND
PURPOSE: This investigation aimed to establish the basis of a pharmacotherapy for nifedipine-induced gingival overgrowth. Gingival overgrowth has been attributed to the enhanced growth of gingival fibroblasts. In this study, we investigated the effects of 18-α-glycyrrhetinic acid (18α-GA) on growth, the cell cycle, and apoptosis and on the regulators of these processes in gingival fibroblasts isolated from patients who presented with nifedipine-induced gingival overgrowth. EXPERIMENTAL APPROACH: Gingival fibroblasts were cultured in medium containing 1% FBS with/without 10 μM 18α-GA for 24 or 48 h, and the cell number, cell cycle phase distribution, relative DNA content, apoptotic cell number and morphological characteristics of the cells undergoing apoptosis were measured together with the levels of proteins that regulate these processes and the level of caspase activity. KEY
RESULTS: 18α-GA significantly decreased cell numbers and significantly increased the percentage of cells in the sub-G1 and G0 /G1 phases of the cell cycle and the number of apoptotic cells. Nuclear condensation and fragmentation of cells into small apoptotic bodies appeared in the fibroblasts treated with 18α-GA. In addition, 18α-GA significantly decreased the protein levels of cyclins A and D1, CDKs 2 and 6, phosphorylated Rb (ser(780) and ser(807/811)), Bcl-xL and Bcl-2 and increased the protein levels of p27, cytosolic cytochrome c, pro-caspase-3, and cleaved caspase-3 and the activities of caspases 3 and 9. CONCLUSIONS AND IMPLICATIONS: 18α-GA inhibited gingival fibroblast growth by suppressing the G1 /S phase transition and inducing apoptosis. In conclusion, 18α-GA may be used as a pharmacotherapy for nifedipine-induced gingival overgrowth.
© 2015 The British Pharmacological Society.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26676684      PMCID: PMC4761096          DOI: 10.1111/bph.13410

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  56 in total

1.  Activation of caspase-9, but not caspase-2 or caspase-8, is essential for heat-induced apoptosis in Jurkat cells.

Authors:  Shary N Shelton; Cindy D Dillard; John D Robertson
Journal:  J Biol Chem       Date:  2010-10-26       Impact factor: 5.157

2.  Experimental design and analysis and their reporting: new guidance for publication in BJP.

Authors:  Michael J Curtis; Richard A Bond; Domenico Spina; Amrita Ahluwalia; Stephen P A Alexander; Mark A Giembycz; Annette Gilchrist; Daniel Hoyer; Paul A Insel; Angelo A Izzo; Andrew J Lawrence; David J MacEwan; Lawrence D F Moon; Sue Wonnacott; Arthur H Weston; John C McGrath
Journal:  Br J Pharmacol       Date:  2015-07       Impact factor: 8.739

Review 3.  Role of the Rb/E2F pathway in cell growth control.

Authors:  J R Nevins; G Leone; J DeGregori; L Jakoi
Journal:  J Cell Physiol       Date:  1997-11       Impact factor: 6.384

4.  18β-Glycyrrhetinic acid potentiates apoptotic effect of trichostatin A on human epithelial ovarian carcinoma cell lines.

Authors:  Chung Soo Lee; Jae Chon Yang; Yun Jeong Kim; Eun-Ra Jang; Wonyong Kim; Soon Chul Myung
Journal:  Eur J Pharmacol       Date:  2010-09-22       Impact factor: 4.432

5.  Ubiquitin C-terminal hydrolase L1 (UCH-L1) acts as a novel potentiator of cyclin-dependent kinases to enhance cell proliferation independently of its hydrolase activity.

Authors:  Tomohiro Kabuta; Takeshi Mitsui; Masaki Takahashi; Yuuki Fujiwara; Chihana Kabuta; Chiho Konya; Yukihiro Tsuchiya; Yusuke Hatanaka; Kenko Uchida; Hirohiko Hohjoh; Keiji Wada
Journal:  J Biol Chem       Date:  2013-03-29       Impact factor: 5.157

6.  Epithelial cell rests of Malassez modulate cell proliferation, differentiation and apoptosis via gap junctional communication under mechanical stretching in vitro.

Authors:  Ken Haku; Takashi Muramatsu; Arisa Hara; Akira Kikuchi; Sadamitsu Hashimoto; Takashi Inoue; Masaki Shimono
Journal:  Bull Tokyo Dent Coll       Date:  2011

7.  Tumorigenic effects of endocrine-disrupting chemicals are alleviated by licorice (Glycyrrhiza glabra) root extract through suppression of AhR expression in mammalian cells.

Authors:  Xiao Ting Chu; Joseph de la Cruz; Seong Gu Hwang; Heeok Hong
Journal:  Asian Pac J Cancer Prev       Date:  2014

8.  Differences of cell growth and cell cycle regulators induced by basic fibroblast growth factor between nifedipine responders and non-responders.

Authors:  Reiri Takeuchi; Hiroko Matsumoto; Hidehiko Okada; Mami Hori; Akihiko Gunji; Kosuke Hakozaki; Yoshiaki Akimoto; Akira Fujii
Journal:  J Pharmacol Sci       Date:  2007-02-08       Impact factor: 3.337

9.  Inhibition of G₁ cell cycle arrest in human gingival fibroblasts exposed to phenytoin.

Authors:  Reiri Takeuchi; Hiroko Matsumoto; Yoshiaki Akimoto; Akira Fujii
Journal:  Fundam Clin Pharmacol       Date:  2012-08-14       Impact factor: 2.748

10.  Germ line gain of function with SOS1 mutation in hereditary gingival fibromatosis.

Authors:  Shyh-Ing Jang; Eun-Jin Lee; P Suzanne Hart; Mukundhan Ramaswami; Debora Pallos; Thomas C Hart
Journal:  J Biol Chem       Date:  2007-05-17       Impact factor: 5.157

View more
  2 in total

1.  Possible pharmacotherapy for nifedipine-induced gingival overgrowth: 18α-glycyrrhetinic acid inhibits human gingival fibroblast growth.

Authors:  R Takeuchi; K Hiratsuka; K Arikawa; M Ono; M Komiya; Y Akimoto; A Fujii; H Matsumoto
Journal:  Br J Pharmacol       Date:  2016-02-03       Impact factor: 8.739

2.  miR-4651 inhibits cell proliferation of gingival mesenchymal stem cells by inhibiting HMGA2 under nifedipine treatment.

Authors:  Xiao Han; Ruzhuang Yang; Haoqing Yang; Yangyang Cao; Nannan Han; Chen Zhang; Ruitang Shi; Zhengting Zhang; Zhipeng Fan
Journal:  Int J Oral Sci       Date:  2020-03-31       Impact factor: 6.344

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.